CIBEROBN researchers have conducted a study that demonstrates that the one known as 'glycation gap' could be used as a "thermometer" to control diabetes and know the chances of vascular diseases, nephropathy, retinopathy or neuropathy.
Glycation is the spontaneous union of glucose to different physiological proteins.For its part, the glycation gap refers to the different degree of glycation in diabetes patients with similar blood glucose levels.
"There are people with high glucose who spend the years and practically have no complications, and vice versa, others who control their diabetes and are fatal," explains the Cyberbon researcher and main author of the study, Santiago Rodríguez Segade.
The study, which is published in the last issue of 'Clinical Chemistry', points out that type 2 diabetics that are high glycadores are more likely to suffer vascular diseases, nephropathy, retinopathy or neuropathy.
Therefore, these data "support" the hypothesis of the so -called 'glycation gap', which acts as a "thermometer" according to which for the same level of medium blood glucose there are patients who are low, moderate and high glycadores, who canconsequence develop different degrees of microvascular complications.
To carry out the research, the team has analyzed the data of a cohort carried out for 14 years on 2,314 patients with type 2 diabetes. In the follow -up, patients were valued to diabetic nephropathy according to the subjects had a low glycation level, moderate or high.
To calculate the 'glycation gap', the authors used glyd hemoglobin tests (indicatedthe previous two weeks and indicate extracellular glycation).
"The clinician can handle each patient does he know if he is high or low glycador and can better adjust the dose in each case," says Santiago Rodríguez, who warns that this test does not remain important to the "usual" test ofglyd hemoglobin, but provides "additional and complementary information."
